LAG-3/PD-1 Inhibitor Therapy in Unresectable or Metastatic Melanoma: The RELATIVITY-047 Trial

Video

Sajeve Thomas, MD, reflects on the RELATIVITY-047 trial combining relatlimab, a LAG-3 inhibitor, with nivolumab, a PD-1 inhibitor, in the first-line setting of unresectable or metastatic melanoma.

Transcript:

Sajeve S. Thomas, MD: Ultimately these are 2 distinct inhibitory checkpoints, and if you can target both LAG-3 and PD-1, you can get a synergistic response and a better response of trying to turn on these T-cells and shrink tumors, and that’s essentially what the LAG-3 is doing. It is another distinct inhibitory checkpoint. The rationale for¼this combination is to get better responses, but hopefully without seeing as many adverse effects as we’ve seen with other combinations. The RELATIVITY-047 trial (NCT03470922) was a randomized phase 3 study, a¼global study randomizing patients with metastatic melanoma. About 700 patients received nivolumab and relatlimab, versus nivolumab alone. These were patients with unresected melanoma stage IV disease. If you had autoimmune [disease], you were excluded. If you required steroids for other medical issues, you were excluded. The primary end point was progression-free survival. The secondary end points were overall survival and response rate.

In the clinical trial, the primary end point was progression-free survival. For patients who had nivolumab, the median progression-free survival was roughly 4.6 months. If you got nivo and rela, the median progression-free survival was 10.1 months, so a distinct, significant improvement in progression-free survival. Regardless of whether you’re BRAF mutated or wild type, the progression-free survival with nivo and rela was approximately the same amount, at 10 months.

If you look at ipilimumab/nivolumab, it was roughly 16 to 17 months in terms of median progression-free survival. If you looked at LAG-3 status, because they did look at PD-1 and LAG-3 status, if you were more than 1% than the median progression-free survival, it was roughly about 12 months. If you were less than 1%, it was median progression-free survival of about 4 months. If you look at overall survival, there was descriptively a change in better overall survival for those who got nivo and rela, but this was not a significant difference. So, hopefully, there are more follow-ups to see if there’s some significant difference in overall survival. In terms of response rate, nivo had a response rate of roughly 33%, and nivo and rela was about 43%, so about 10% improvement in response rate with the combination of nivo and rela. When we talk about safety issues, compared with the ipi/nivo combination, which has grade 3/grade 4 events of 50%, 55%, nivo and rela was roughly about 18% to 20% in terms of grade 3/grade 4 adverse events.

Transcript edited for clarity.

Recent Videos
1 expert in this video
1 expert in this video
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Related Content